• Thurs news: AbbVie Parkinson’s drug. Arch raises $3B biotech fund. Biogen dropping failed Sage tremor drug. AZ gets sought-after Tagrisso OK. Pfizer withdrawing sickle cell med. See more on our front page

The PROBLEM is FLEMMING

Not sure if anyone could do any better as acne and rosacea are dead and future is biologics. We missed the boat and now the end is near. At least we have Consumer and Aesthetics which should be the emphasis going forward.
 




Not sure if anyone could do any better as acne and rosacea are dead and future is biologics. We missed the boat and now the end is near. At least we have Consumer and Aesthetics which should be the emphasis going forward.
Cetaphil losing out against CeraVe. Nothing new in Aesthetics for several years.
 












“High EQ & well-honed “soft skills” to inspire, motivate and mobilize large cross-functional teams toward a common end-goal”

from a job posting in Switzerland. Obviously the same skills don’t apply to Fleming! What a joke!
 




Fleming, you won't be able to grow a business when you have NO talent working here. SINKING SHIP!!!!!! Galderma is getting a bad reputation. FO and TD have no idea how to manage anything - its pretty obvious they are blowing smoke..until their payout and parachute opens.
 








We are becoming more ineffective and inefficient under Fleming’s scatter- brained direction and organization. His knee jerk reactions are irrational, no solid leadership or vision. Only fear. It is more than time for him to go.
 
























Similar threads

Replies
8
Views
2K
Replies
27
Views
3K
Replies
4
Views
856
Replies
38
Views
4K